Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M

Argenx, a Dutch firm with a pipeline of investigational antibody-based therapies, will pay San Diego-based Halozyme to use its drug delivery technology to develop subcutaneous versions of some of the drugs Argenx is developing to treat rare autoimmune diseases and cancers.

The technology Halozyme (NASDAQ: HALO) is licensing, called Enhanze, allows drugs that would otherwise be delivered intravenously to be injected, which can turn an hours-long process into one that lasts just minutes.

Argenx (NASDAQ: ARGXagreed to pay Halozyme $30 million up front for exclusive use of the technology for drugs that target the FcRn receptor. One such… Read more »

READ  Synlogic Promotes Aoife Brennan to President & CEO

Leave a Reply